NO20070956L - Tumonnalsokende celler konstruert for a produsere tumornekrosefaktor-beslektet apoptoseinduscrende ligand (TRAIL) ved adenoviralmediert genoverforing. - Google Patents

Tumonnalsokende celler konstruert for a produsere tumornekrosefaktor-beslektet apoptoseinduscrende ligand (TRAIL) ved adenoviralmediert genoverforing.

Info

Publication number
NO20070956L
NO20070956L NO20070956A NO20070956A NO20070956L NO 20070956 L NO20070956 L NO 20070956L NO 20070956 A NO20070956 A NO 20070956A NO 20070956 A NO20070956 A NO 20070956A NO 20070956 L NO20070956 L NO 20070956L
Authority
NO
Norway
Prior art keywords
tumor
necrosis factor
adenoviral
trail
inducing ligand
Prior art date
Application number
NO20070956A
Other languages
English (en)
Norwegian (no)
Inventor
Francesco Colotta
Alessandro Massimo Gianni
Carmelo Carlo Stella
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of NO20070956L publication Critical patent/NO20070956L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20070956A 2004-07-29 2007-02-20 Tumonnalsokende celler konstruert for a produsere tumornekrosefaktor-beslektet apoptoseinduscrende ligand (TRAIL) ved adenoviralmediert genoverforing. NO20070956L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
PCT/EP2005/007957 WO2006010558A1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Publications (1)

Publication Number Publication Date
NO20070956L true NO20070956L (no) 2007-02-20

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070956A NO20070956L (no) 2004-07-29 2007-02-20 Tumonnalsokende celler konstruert for a produsere tumornekrosefaktor-beslektet apoptoseinduscrende ligand (TRAIL) ved adenoviralmediert genoverforing.

Country Status (25)

Country Link
US (1) US20070264231A1 (sr)
EP (2) EP1621550A1 (sr)
JP (1) JP5042826B2 (sr)
KR (1) KR20070047757A (sr)
CN (1) CN101076540B (sr)
AT (1) ATE455847T1 (sr)
AU (1) AU2005266543B2 (sr)
BR (1) BRPI0513855A (sr)
CA (1) CA2571426A1 (sr)
DE (1) DE602005019050D1 (sr)
DK (1) DK1771468T3 (sr)
ES (1) ES2340400T3 (sr)
HK (1) HK1110874A1 (sr)
HR (1) HRP20100227T1 (sr)
IL (1) IL180233A (sr)
MX (1) MX2007001152A (sr)
NO (1) NO20070956L (sr)
NZ (1) NZ552223A (sr)
PL (1) PL1771468T3 (sr)
PT (1) PT1771468E (sr)
RS (1) RS51381B (sr)
RU (1) RU2390558C2 (sr)
SI (1) SI1771468T1 (sr)
WO (1) WO2006010558A1 (sr)
ZA (1) ZA200701231B (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070050911A (ko) * 2004-06-18 2007-05-16 제넨테크, 인크. Ａｐｏ２ｌ 수용체 작동제 및 ｎｋ 세포 활성화제의 사용방법
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
WO2008142862A1 (ja) * 2007-05-18 2008-11-27 National University Corporation Asahikawa Medical College 血管内皮前駆細胞の移植による抗がん療法
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
EP2811023B1 (en) * 2012-02-01 2018-10-24 Postech Academy-Industry Foundation Vector simultaneously expressing dodecameric trail and hsv-tk suicide genes, and anticancer stem cell therapeutic agent using same
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
EP3209382B1 (en) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
ES2890859T3 (es) 2015-07-29 2022-01-24 Onk Therapeutics Ltd Células asesinas naturales modificadas y líneas de células asesinas naturales que tienen citotoxicidad aumentada
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US20220143089A1 (en) * 2019-03-21 2022-05-12 Onk Therapeutics Limited Modified immune effector cells with increased resistance to cell death
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332435T3 (es) * 1997-06-04 2010-02-04 Oxford Biomedica (Uk) Limited Vector dirigido a tumores.
AU2001290720A1 (en) * 2000-09-11 2002-03-26 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
WO2002066044A2 (en) * 2000-10-24 2002-08-29 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
SI1771468T1 (sl) 2010-07-30
HK1110874A1 (en) 2008-07-25
EP1771468B1 (en) 2010-01-20
WO2006010558A1 (en) 2006-02-02
ES2340400T3 (es) 2010-06-02
JP5042826B2 (ja) 2012-10-03
NZ552223A (en) 2009-01-31
RS51381B (sr) 2011-02-28
PL1771468T3 (pl) 2010-07-30
KR20070047757A (ko) 2007-05-07
AU2005266543A1 (en) 2006-02-02
CN101076540B (zh) 2012-10-24
RU2390558C2 (ru) 2010-05-27
EP1771468A1 (en) 2007-04-11
IL180233A (en) 2010-12-30
DE602005019050D1 (de) 2010-03-11
CA2571426A1 (en) 2006-02-02
AU2005266543B2 (en) 2012-02-02
RU2007107369A (ru) 2008-09-10
DK1771468T3 (da) 2010-05-25
MX2007001152A (es) 2007-04-18
BRPI0513855A (pt) 2008-05-20
JP2008507961A (ja) 2008-03-21
PT1771468E (pt) 2010-04-20
HRP20100227T1 (hr) 2010-07-31
ZA200701231B (en) 2008-08-27
CN101076540A (zh) 2007-11-21
ATE455847T1 (de) 2010-02-15
IL180233A0 (en) 2007-07-04
US20070264231A1 (en) 2007-11-15
EP1621550A1 (en) 2006-02-01
WO2006010558A8 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
NO20070956L (no) Tumonnalsokende celler konstruert for a produsere tumornekrosefaktor-beslektet apoptoseinduscrende ligand (TRAIL) ved adenoviralmediert genoverforing.
HK1109421A1 (en) Chimeric adenoviruses for use in cancer treatment
WO2009046141A3 (en) Antisense modulation of fibroblast growth factor receptor 4 expression
MX340736B (es) Vacunas y componentes de vacunas para inhibicion de celulas microbianas.
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2007130604A3 (en) Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
EP1824872A4 (en) RNAI MODULATION OF MLL-AF4 AND USES THEREOF
EP4242236A3 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
MX2009012846A (es) Polipeptidos que tienen actividad celulosica mejorada y polinucleotidos que los codifican.
EA201300279A1 (ru) Устойчивая к sclerotinia brassica и способы развития устойчивости к sclerotinia
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
TW200621284A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2006110240A3 (en) Gene transfer with adenoviruses having modified fiber proteins
MX2022005670A (es) Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn.
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2020207510A3 (zh) 基因在促进水稻籽粒产量上的应用
WO2008133137A1 (ja) 遺伝子治療のためのベクター
WO2005014607A3 (en) Antisense modulation of stearoyl-coa desaturase expression
WO2005010149A3 (en) Subgroup b adenoviral vectors for treating disease
WO2008067025A3 (en) Oncolytic adenoviruses and uses thereof
TW200621285A (en) Polypeptides having antimicrobial activity and polyncleotides encoding same
GB0517292D0 (en) Cell migration modulating compounds
MX2010006425A (es) Moduladores de proteina cinasa de objetivos multiples 1,3-ciclopentadiona-substituida de cancer, angiogenesis y las trayectorias inflamatorias asociadas con los mismos.
WO2008037490A3 (en) Galactosyltransferase
MY150196A (en) Rumc peptides with antimicrobial activity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application